FRANKFURT (dpa-AFX) – Evotec shares are expected to continue their strong rally from the past two trading days on Thursday. On Tradegate, the pharmaceutical research company's stock rose 2.4 percent to €6.44 compared to the previous day's Xetra close. This would represent a total gain of around 17 percent since Tuesday.
As announced by the Hamburg-based company on Thursday morning, its U.S. subsidiary Just Biologics has received new funding from the Gates Foundation to support AI-driven optimization of monoclonal antibody development capabilities.
In the previous two days, Evotec shares had already been buoyed by Amgen's announcement of its planned acquisition of British biotech firm Dark Blue Therapeutics for up to $840 million. Evotec stands to benefit, as the company reportedly holds a roughly 21 percent stake in Dark Blue, according to RBC. Furthermore, the acquisition has also fueled takeover speculation surrounding Evotec, according to market observers./ck/mis
